- Home
- TRUG vs IMRN Comparison
TRUG vs IMRN Comparison
Compare TRUG & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRUG
- IMRN
- Stock Information
- Founded
- TRUG 1983
- IMRN 1994
- Country
- TRUG United States
- IMRN Australia
- Employees
- TRUG N/A
- IMRN N/A
- Industry
- TRUG
- IMRN Biotechnology: Pharmaceutical Preparations
- Sector
- TRUG
- IMRN Health Care
- Exchange
- TRUG NYSE
- IMRN Nasdaq
- Market Cap
- TRUG 10.9M
- IMRN 10.3M
- IPO Year
- TRUG N/A
- IMRN N/A
- Fundamental
- Price
- TRUG $0.23
- IMRN $1.71
- Analyst Decision
- TRUG Strong Buy
- IMRN Strong Buy
- Analyst Count
- TRUG 1
- IMRN 1
- Target Price
- TRUG $2.00
- IMRN $5.00
- AVG Volume (30 Days)
- TRUG 1.8M
- IMRN 11.8K
- Earning Date
- TRUG 04-15-2025
- IMRN 05-27-2025
- Dividend Yield
- TRUG N/A
- IMRN N/A
- EPS Growth
- TRUG N/A
- IMRN N/A
- EPS
- TRUG N/A
- IMRN N/A
- Revenue
- TRUG $21,858,864.00
- IMRN $4,048,286.00
- Revenue This Year
- TRUG $24.05
- IMRN N/A
- Revenue Next Year
- TRUG $31.65
- IMRN N/A
- P/E Ratio
- TRUG N/A
- IMRN N/A
- Revenue Growth
- TRUG 6.19
- IMRN 82.90
- 52 Week Low
- TRUG $0.22
- IMRN $1.60
- 52 Week High
- TRUG $1.60
- IMRN $2.87
- Technical
- Relative Strength Index (RSI)
- TRUG 36.70
- IMRN 41.94
- Support Level
- TRUG $0.21
- IMRN $1.87
- Resistance Level
- TRUG $0.25
- IMRN $2.13
- Average True Range (ATR)
- TRUG 0.03
- IMRN 0.15
- MACD
- TRUG -0.00
- IMRN -0.01
- Stochastic Oscillator
- TRUG 16.12
- IMRN 32.71
About TRUG TRUGOLF HOLDINGS INC
TruGolf Holdings Inc is a indoor golf gaming solutions company. It has built video games (including Links, a sports game for PC), hardware solutions, and an all-new e-sports platform to connect golfers around the world with E6 CONNECT.
About IMRN Immuron Limited
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.